The biopsy of the sentinel lymph node in multicentric breast carcinoma. Our experience
Keywords:
multicentric breast cancer, sentinel lymph node biopsyAbstract
The biopsy of the sentinel lymph node (SLN) was considered an unreliable method in multicentric breast carcinomas. The Authors, revising old theories of the lymphatic drainage of the breast, demonstrate that the lymphatic outflow, following the ductal system, converges in the subareolar plexus and, from here, to the axillary lymphatic chain. Thus, the concept of “SLN of the breast” and not “SLN of the tumor” was born. These anatomical premises represent the rational of our study, that is to estimate the feasibility and the accuracy of the SLN biopsy after subareolar injection of radioactive tracer and vital dye in patients affected by multicentric carcinoma of the breast. From November 2005 to November 2008, 11 patients with multicentric carcinomas underwent the identification of sentinel lymph node by subareolar injection of radioactive tracer, surgical biopsy and total axillary lympho-adenectomy. This technique, although the limited number of cases, demonstrated a high degree of identification of SLN and a low incidence of false-negative cases. In conclusion, from our study it emerges that the axillary sentinel lymph node is representative of the entire mammary gland, the multicentric breast cancer would not any more be considered an absolute contraindication, and the subareolar injection of tracing could be the best technical option.Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.